Immunoregulatory gene polymorphisms are associated with ANCA-related vasculitis

Clinical Immunology

Volumn 128, Issue 1, 2008, Pages 39-45

  Slot, Marjan C ^a   Sokolowska, Milena G ^a,b   Savelkouls, Kim G ^a   Janssen, Rob G J H ^c   Damoiseaux, Jan G M C ^a   Cohen Tervaert, Jan Willem ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

ANCA; CTLA 4; PD 1; SNP; Vasculitis; Wegener's granulomatosis, Promoter polymorphism

Indexed keywords

ADENINE; CYTOSINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GUANINE; MICROSATELLITE DNA; NEUTROPHIL CYTOPLASMIC ANTIBODY; PROTEIN PD1; REGULATOR PROTEIN; THYMINE;

3' UNTRANSLATED REGION; ADULT; AGED; ALLELE; ANCA ASSOCIATED VASCULITIS; ARTICLE; CONTROLLED STUDY; CTLA4 GENE; FEMALE; GENE; GENETIC POLYMORPHISM; HOMOZYGOSITY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PDCD1 GENE; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE ACTIVATION; WEGENER GRANULOMATOSIS;

ADULT; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIGENS, CD; APOPTOSIS REGULATORY PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASCULITIS;

EID: 49949152482     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2008.03.506     Document Type: Article

References (45)

1. Cohen Tervaert J.W., Goldschmeding R., Elema J.D., van der Giessen M., Huitema M.G., van der Hem G.K., The T.H., von dem Borne A.E., and Kallenberg C.G. Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis. Kidney Int. 37 (1990) 799-806
2. Jennette J.C., and Falk R.J. Small-vessel vasculitis. N. Engl. J. Med. 337 (1997) 1512-1523
3. Velosa J.A., Homburger H.A., and Holley K.E. Prospective study of anti-neutrophil cytoplasmic autoantibody tests in the diagnosis of idiopathic necrotizing-crescentic glomerulonephritis and renal vasculitis. Mayo Clin. Proc. 68 (1993) 561-565
4. Cohen Tervaert J.W., van der Woude F.J., Fauci A.S., Ambrus J.L., Velosa J., Keane W.F., Meijer S., van der Giessen M., van der Hem G.K., The T.H., et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch. Intern. Med. 149 (1989) 2461-2465
5. Boomsma M.M., Stegeman C.A., van der Leij M.J., Oost W., Hermans J., Kallenberg C.G., Limburg P.C., and Cohen Tervaert J.W. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum. 43 (2000) 2025-2033
6. Falk R.J., Terrell R.S., Charles L.A., and Jennette J.C. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 4115-4119
7. Muller Kobold A.C., van der Geld Y.M., Limburg P.C., Cohen Tervaert J.W., and Kallenberg C.G. Pathophysiology of ANCA-associated glomerulonephritis. Nephrol. Dial. Transplant. 14 (1999) 1366-1375
8. Heeringa P., Brouwer E., Cohen Tervaert J.W., Weening J.J., and Kallenberg C.G. Animal models of anti-neutrophil cytoplasmic antibody associated vasculitis. Kidney Int. 53 (1998) 253-263
9. Xiao H., Heeringa P., Hu P., Liu Z., Zhao M., Aratani Y., Maeda N., Falk R.J., and Jennette J.C. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J. Clin. Invest. 110 (2002) 955-963
10. Clayton A.R., and Savage C.O. What you should know about PR3-ANCA. Evidence for the role of T cells in the pathogenesis of systemic vasculitis. Arthritis Res. 2 (2000) 260-262
11. King W.J., Brooks C.J., Holder R., Hughes P., Adu D., and Savage C.O. T lymphocyte responses to anti-neutrophil cytoplasmic autoantibody (ANCA) antigens are present in patients with ANCA-associated systemic vasculitis and persist during disease remission. Clin. Exp. Immunol. 112 (1998) 539-546
12. Popa E.R., Franssen C.F., Limburg P.C., Huitema M.G., Kallenberg C.G., and Cohen Tervaert J.W. In vitro cytokine production and proliferation of T cells from patients with anti-proteinase 3- and antimyeloperoxidase-associated vasculitis, in response to proteinase 3 and myeloperoxidase. Arthritis Rheum. 46 (2002) 1894-1904
13. Rasmussen N., and Petersen J. Cellular immune responses and pathogenesis in c-ANCA positive vasculitides. J. Autoimmun. 6 (1993) 227-236
14. Cunningham M.A., Huang X.R., Dowling J.P., Tipping P.G., and Holdsworth S.R. Prominence of cell-mediated immunity effectors in "pauci-immune" glomerulonephritis. J. Am. Soc. Nephrol. 10 (1999) 499-506
15. Schmitt W.H., Heesen C., Csernok E., Rautmann A., and Gross W.L. Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Association with disease activity. Arthritis Rheum. 35 (1992) 1088-1096
16. Stegeman C.A., Cohen Tervaert J.W., Huitema M.G., and Kallenberg C.G. Serum markers of T cell activation in relapses of Wegener's granulomatosis. Clin. Exp. Immunol. 91 (1993) 415-420
17. Giscombe R., Nityanand S., Lewin N., Grunewald J., and Lefvert A.K. Expanded T cell populations in patients with Wegener's granulomatosis: characteristics and correlates with disease activity. J. Clin. Immunol. 18 (1998) 404-413
18. Popa E.R., Stegeman C.A., Bos N.A., Kallenberg C.G., and Cohen Tervaert J.W. Differential B- and T-cell activation in Wegener's granulomatosis. J. Allergy Clin. Immunol. 103 (1999) 885-894
19. Prokunina L., Castillejo-Lopez C., Oberg F., Gunnarsson I., Berg L., Magnusson V., Brookes A.J., Tentler D., Kristjansdottir H., Grondal G., Bolstad A.I., Svenungsson E., Lundberg I., Sturfelt G., Jonssen A., Truedsson L., Lima G., Alcocer-Varela J., Jonsson R., Gyllensten U.B., Harley J.B., Alarcon-Segovia D., Steinsson K., and Alarcon-Riquelme M.E. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat. Genet. 32 (2002) 666-669
20. Lin S.C., Yen J.H., Tsai J.J., Tsai W.C., Ou T.T., Liu H.W., and Chen C.J. Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus. Arthritis Rheum. 50 (2004) 770-775
21. Huang D., Giscombe R., Zhou Y., and Lefvert A.K. Polymorphisms in CTLA-4 but not tumor necrosis factor-alpha or interleukin 1beta genes are associated with Wegener's granulomatosis. J. Rheumatol. 27 (2000) 397-401
22. Giscombe R., Wang X., Huang D., and Lefvert A.K. Coding sequence 1 and promoter single nucleotide polymorphisms in the CTLA-4 gene in Wegener's granulomatosis. Rheumatol. 29 (2002) 950-953
23. Zhou Y., Huang D., Paris P.L., Sauter C.S., Prock K.A., and Hoffman G.S. An analysis of CTLA-4 and proinflammatory cytokine genes in Wegener's granulomatosis. Arthritis Rheum. 50 (2004) 2645-2650
24. Ligers A., Teleshova N., Masterman T., Huang W.X., and Hillert J. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun. 2 (2001) 145-152
25. Huang D., Giscombe R., Zhou Y., Pirskanen R., and Lefvert A.K. Dinucleotide repeat expansion in the CTLA-4 gene leads to T cell hyper-reactivity via the CD28 pathway in myasthenia gravis. J. Neuroimmunol. 105 (2000) 69-77
26. Kouki T., Sawai Y., Gardine C.A., Fisfalen M.E., Alegre M.L., and DeGroot L.J. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J. Immunol. 165 (2000) 6606-6611
27. Jennette J.C., Falk R.J., Andrassy K., Bacon P.A., Churg J., Gross W.L., Hagen E.C., Hoffman G.S., Hunder G.G., Kallenberg C.G.M., McCluskey R.T., Sinco R.A., Rees A.J., van Es L.A., Waldherr R., and Wiik A. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 37 (1994) 187-192
28. Donner H., Rau H., Walfish P.G., Braun J., Siegmund T., Finke R., Herwig J., Usadel K.H., and Badenhoop K. CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus. J. Clin. Endocrinol. Metab. 82 (1997) 143-146
29. Deichmann K., Heinzmann A., Bruggenolte E., Forster J., and Kuehr J. An Mse I RFLP in the human CTLA4 promotor. Biochem. Biophys. Res. Commun. 225 (1996) 817-818
30. Hudson L.L., Rocca K., Song Y.W., and Pandey J.P. CTLA-4 gene polymorphisms in systemic lupus erythematosus: a highly significant association with a determinant in the promoter region. Hum. Genet. 111 (2002) 452-455
31. Yanagawa T., Hidaka Y., Guimaraes V., Soliman M., and DeGroot L.J. CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population. Clin. Endocrinol. Metab. 80 (1995) 41-45
32. Sharpe A.H., and Freeman G.J. The B7-CD28 superfamily. Nat. Rev., Immunol. 2 (2002) 116-126
33. Tivol E.A., Borriello F., Schweitzer A.N., Lynch W.P., Bluestone J.A., and Sharpe A.H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3 (1995) 541-547
34. Shaw G., and Kamen R. A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 46 (1986) 659-667
35. Polymeropoulos M.H., Xiao H., Rath D.S., and Merril C.R. Dinucleotide repeat polymorphism at the human CTLA4 gene. Nucleic Acids Res. 19 (1991) 4018
36. Lee Y.H., Kim Y.R., Ji J.D., Sohn J., and Song G.G. Polymorphisms of the CTLA-4 exon 1 and promoter gene in systemic lupus erythematosus. Lupus 10 (2001) 601-605
37. Pullmann Jr. R., Lukac J., Skerenova M., Rovensky J., Hybenova J., Melus V., Celec S., Pullmann R., and Hyrdel R. Cytotoxic T lymphocyte antigen 4 (CTLA-4) dimorphism in patients with systemic lupus erythematosus. Clin. Exp. Rheumatol. 17 (1999) 725-729
38. Braun J., Donner H., Siegmund T., Walfish P.G., Usadel K.H., and Badenhoop K. CTLA-4 promoter variants in patients with Graves' disease and Hashimoto's thyroiditis. Tissue Antigens 51 (1998) 563-566
39. Ligers A., Xu C., Saarinen S., Hillert J., and Olerup O. The CTLA-4 gene is associated with multiple sclerosis. Neuroimmunol. 97 (1999) 182-190
40. Freeman G.J., Long A.J., Iwai Y., Bourque K., Chernova T., Nishimura H., Fitz L.J., Malenkovich N., Okazaki T., Byrne M.C., Horton H.F., Fouser L., Carter L., Ling V., Bowman M.R., Carreno B.M., Collins M., Wood C.R., and Honjo T. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192 (2000) 1027-1034
41. Nishimura H., Nose M., Hiai H., Minato N., and Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11 (1999) 141-151
42. Prokunina L., Gunnarsson I., Sturfelt G., Truedsson L., Seligman V.A., Olson J.L., Seldin M.F., Criswell L.A., and Alarcon-Riquelme M.E. The systemic lupus erythematosus-associated PDCD1 polymorphism PD1.3A in lupus nephritis. Arthritis Rheum. 50 (2004) 327-328
43. Prokunina L., Padyukov L., Bennet A., de Faire U., Wiman B., Prince J., Alfredsson L., Klareskog L., and Alarcon-Riquelme M. Association of the PD-1.3A allele of the PDCD1 gene in patients with rheumatoid arthritis negative for rheumatoid factor and the shared epitope. Arthritis Rheum. 50 (2004) 1770-1773
44. Fernandez-Blanco L., Perez-Pampin E., Gomez-Reino J.J., and Gonzalez A. A CTLA-4 polymorphism associated with susceptibility to systemic lupus erythematosus. Arthritis Rheum. 50 (2004) 328-329
45. Jagiello P., Aries P., Arning L., Wagenleiter S.E., Csernok E., Hellmich B., Gross W.L., and Epplen J.T. The PTPN22 620W allele is a risk factor for Wegener's granulomatosis. Arthritis Rheum. 52 (2005) 4039-4043